Replies to post #97349 on Biotech Values

[DewDiligence]

MNTA:

I have been dismayed by the slow pace of adoption of biogeneric legislation. This market has not materialized nearly as quickly as I had hoped. Amazing that we as a country lament the cost of health care but then move at glacial speed to correct obvious points where cost savings can be gained. Hopefully we see movement on implementing biogenerics in the near future. I'd hate to think NVS (and MNTA) will have to sue FDA (as was done with omnitrope) to force them to move.

Although some people might disagree, I don’t think there’s a connection between the recently enacted US legislation for FoB’s and what the FDA ends up doing with respect to generic Lovenox. The FDA has clear authority to approve generic Lovenox based on statutes that have been in effect since 1984.